High impact
Abbott Labs and Danaher both reported Q1 2026 results, with Abbott's everyday products outperforming Danaher's slumping biotech equipment, and the post suggests choosing the wrong stock may cost significant returns.
Finnhub07/11, 01:18 AM
Related assets
Coming up for ABT
Explore next
Latest ABT news
Bloomberg08/21, 04:57 PM
FirstSquawk08/21, 06:28 AM
FirstSquawk08/21, 06:28 AM